Paxlovid may not benefit greatly from the elderly who have been fortified
MWe are very emulated now in the Covid-19 management, with a shield of previous infections, vaccines, self-tests, and antiviral drugs such as Paxlovid.
However, in the recent study, the researchers stated that taking a bachelvide may not provide much of the benefit that doctors originally believe – especially for the elderly who are vaccinated.
in Search letter Posted in mosque On February 20, Dr. John Mavi used a co -professor of medicine at David Given Medical College at the University of California, Los Angeles, and his fellow Canadian colleagues used to explore what happened when people took Bachelvid. The Canadian health policy in 2022 allowed the medical prescriptions of Paxlovid only for persons of symptoms at the age of 70 in order to reserve the drug for those who need it more. The elderly are at risk of complications from Covid-19. Politics allowed scientists to compare people in this age group who took Pakselovide for those who did not.
Of nearly 1.5 million people who studied, those who received recipes for the drug did not have significantly different rates to enter the hospital or death from Covid-19 from those who did not get the medicine. Most of the people who studied.
“The main result was that among the older adults, Baccalaovide has not appeared any statistically significant decrease in Covid-19 hospitals or in deaths,” says Mavi, the lead author of the study.
This is completely different from the results made by Paxlovid, Pfizer, first It was mentioned in 2022. In that study, Faizer found that the drug was reduced from hospitals and deaths from Covid-19 by 89 % compared to people receiving the placebo. But the group they studied was mostly in middle and immune, and it is a lot different from the population today. “However, the 2022 pfizer study was and is still used to support the assumption that the benefits of Paxlovid in unjust adults also applied to the vaccinated adults,” says Mavi. “This is used to justify its perceived effectiveness – the price of its list at 1650 dollars per treatment cycle.”
In a statement, Pfizer said that it is not possible to comment on a study that you did not participate in, but the company “remains”[s] Bexlovid’s clinical event in preventing severe results, including hospitalization and death, from Covid-19 in patients at risk of severe illness. “
Read more: Covid does not always look long as you think
Paxlovid aims to help those at risk of complications from Covid-19, including the elderly, people with the immune system at risk, and those with multiple health conditions. This is still a basic criterion for prescribing the drug, and it is now available for anyone who is 12 years old or older who is at risk of severe diseases.
However, Mavi says there is no strong data on how Paxlovid affects the course of the disease in people who are vaccinated. The results indicate that the benefits are four times smaller than that of Phazer.
“We do not say that Bachelvide is useless,” says Mavi. “What this research says is that its effectiveness in old groups that are more likely to Covid-19, but who have been vaccinated, is much lower than what was previously shown by the non-fortified groups.”
More search is needed, but doctors can consider this new information when determining whether a patient should be recommended to take Paxlovid. Other important factors include a person’s medical history, the danger of the drug for relatively moderate side effects, and bakstalovide, as people who take pixelovide may experience positively again after his negative test.
Dr. Catherine Khan, a distinguished professor of medicine at the University of California, Los Angeles and the chief study in the study, says that she will discuss the latest results with her patients, and “for health individuals in general, I do not encourage or not encourage [Paxlovid] She says, “If they meet the criteria to take it,” she says. “But for people with a risk of disorder or deaths, we are more likely to say that we may think [Paxlovid] At this time, although we do not know 100 % if you will benefit. “
The new study raises questions to research in the future. It does not take into account, for example, how previous infections can cause the body’s response to Paxlovid. Mavi says and that they were also unable to go into the history of vaccinating the participants – how many doses they received – or confirm whether they had taken a pixelovide within five days of their first symptoms, when the drug is more effective. But they are planning to access data on the individual level and do a deeper analysis of other factors that may affect the effectiveness of the drug in reducing hospitals and deaths.
“One of the conclusions of this study is a recommendation for more studies, for each of the elderly and those who are vaccinated, from the effectiveness of Pakselovide,” says Khan.